cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 288, Issue 1 32-1, 2005, Pages

  Phillips, Peter G ^a   Long, Lu ^b   Wilkins, Martin R ^a   Morrell, Nicholas W ^b,c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cyclic nucleotides; Heterogeneity; Smooth muscle cells

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; CICAPROST; CILOSTAMIDE; CYCLIC AMP; ILOPROST; ISOENZYME; MESSENGER RNA; MITOGENIC AGENT; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PROSTACYCLIN DERIVATIVE; ROLIPRAM; VINPOCETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY MUSCLE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HYDROLYSIS; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LUNG ARTERY; LUNG BLOOD VESSEL; LUNG PERFUSION; LUNG VASOCONSTRICTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANOXIA; AORTA; CELL DIVISION; CELLS, CULTURED; CHRONIC DISEASE; CORONARY VESSELS; CYCLIC AMP; DRUG SYNERGISM; INTRACELLULAR MEMBRANES; ISOENZYMES; LUNG; MALE; MYOCYTES, SMOOTH MUSCLE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROSTAGLANDINS I; PULMONARY ARTERY; RATS; RATS, INBRED WKY; RENAL ARTERY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASODILATION;

EID: 11144258648     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00095.2004     Document Type: Article

References (40)

1. Badesch DB, Orton EC, Zapp LM, Westcott JY, Hester J, Voelkel NF, and Stenmark KR. Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am J Respir Cell Mol Biol 1: 489-498, 1989.
2. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, and Brundage BH. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296-302, 1996.
3. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75: 725-748, 1995.
4. Bers DM and Ziolo MT. When is cAMP not cAMP? Effects of compartmentalization. Circ Res 89: 373-375, 2001.
5. Cella G, Bellotto F, Tona F, Sbarai A, Mazzaro G, Motta G, and Fareed J. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 120: 1226-1230, 2001.
6. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, and Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327: 70-75, 1992.
7. + channels play a major role in mediating the vascular effects of iloprost and cicaprost. Eur J Pharmacol 356: 215-224, 1998.
8. Desaubry L, Shoshani I, and Johnson RA. 2′,5′- Dideoxyadenosine 3′-polyphosphates are potent inhibitors of adenylyl cyclases. J Biol Chem 271: 2380-2382, 1996.
9. Dubey RK, Roy A, and Overbeck HW. Culture of renal arteriolar smooth muscle cells. Mitogenic responses to angiotensin II. Circ Res 71: 1143-1152, 1992.
10. Durmowicz AG and Stenmark KR. Mechanisms of structural remodeling in chronic pulmonary hypertension. Pediatr Rev 20: E91-E102, 1999.
11. Fishman AP. Etiology and pathogenesis of primary pulmonary hypertension: a perspective. Chest 114: 242S-247S, 1998.
12. Fujishige K, Kotera J, Yuasa K, and Omori K. The human phosphodiesterase PDE10A gene genomic organization and evolutionary relatedness with other PDEs containing GAF domains. Eur J Biochem 267: 5943-5951, 2000.
13. 2) and its analogs. Prostaglandins 33: 845-854, 1987.
14. Hoffmann R, Abdel'Al S, and Engels P. Differential distribution of rat PDE-7 mRNA in embryonic and adult rat brain. Cell Biochem Biophys 28: 103-113, 1998.
15. Jeffery TK and Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 45: 173-202, 2002.
16. Jeffery TK and Wanstall JC. Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: differences between early and established pulmonary hypertension. J Cardiovasc Pharmacol 32: 213-219, 1998.
17. Johnson BA, Lowenstein CJ, Schwarz MA, Nakayama DK, Pitt BR, and Davies P. Culture of pulmonary microvascular smooth muscle cells from intraacinar arteries of the rat: characterization and inducible production of nitric oxide. Am J Respir Cell Mol Biol 10: 604-612, 1994.
18. Johnson-Mills K, Arauz E, Coffey RG, Krzanowski JJ Jr, and Polson JB. Effect of CI-930 [3-(2H)-pyridazinone-4,5-dihydro-6-[4-(1H-imidazolyl) phenyl]-5-methyl-monohydrochloride] and rolipram on human coronary artery smooth muscle cell proliferation. Biochem Pharmacol 56: 1065-1073, 1998.
19. Karin M and Smeal T. Control, of transcription factors by signal transduction pathways: the beginning of the end. Trends Biochem Sci 17: 418-422, 1992.
20. Liu H and Maurice DH. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125: 1501-1510, 1998.
21. Maclean MR, Johnston ED, McCulloch KM, Pooley L, Houslay MD, and Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 283: 619-624, 1997.
22. McLaughlin VV, Genthner DE, Panella MM, and Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338: 273-277. 1998.
23. Morrell NW, Atochina EN, Morris KG, Danilov SM, and Stenmark KR. Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J Clin Invest 96: 1823-1833, 1995.
24. Morrell NW, Upton PD, Kotecha S, Huntley A, Yacoub MH, Polak JM, and Wharton J. Angiotensin II activates MAPK and stimulates growth of human pulmonary artery smooth muscle via AT1 receptors. Am J Physiol Lung Cell Mol Physiol 277: L440-L448, 1999.
25. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, and Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol Lung Cell Mol Physiol 266: L536-L543, 1994.
26. Schermuly RT, Ghofrani HA, Enke B, Weissmann N, Grimminger F, Seeger W, Schudt C, and Walmrath D. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med 160: 1500-1506, 1999.
27. Schermuly RT, Krupnik E, Tenor H, Schudt C, Weissmann N, Rose F, Grimminger F, Seeger W, Walmrath D, and Ghofrani HA. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am J Respir Crit Care Med 164: 1694-1700, 2001.
28. Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Leuchte H, Grimminger F, Seeger W, and Walmrath D. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 281: L1361-L1368, 2001.
29. Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Schudt C, Tenor H, Grimminger F, Seeger W, and Walmrath D. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 292: 512-520, 2000.
30. 2-adrenoreceptor desensitization. J Biol Chem 273: 20575-20588, 1998.
31. Soderling SH and Beavo JA. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12: 174-179, 2000.
32. Torphy TJ, Zhou HL, and Cieslinski LB. Stimulation of β-adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J Pharmacol Exp Ther 263: 1195-1205, 1992.
33. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, and Voelkel NF. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159: 1925-1932, 1999.
34. 2+ current in rat ventricular myocytes. Br J Pharmacol 127: 65-74, 1999.
35. Wagner RS, Smith CJ, Taylor AM, and Rhoades RA. Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther 282: 1650-1657, 1997.
36. 1-dependent and -independent effects. Arterioscler Thromb Vasc Biol 21: 1928-1933, 2001.
37. Wanstall JC and O'Donnell SM. Responses to vasodilator drugs on pulmonary artery preparations from pulmonary hypertensive rats. Br J Pharmacol 105: 152-158, 1992.
38. Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, and Morrell NW. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 102: 3130-3136, 2000.
39. 2+ signals. Curr Opin Cell Biol 14: 160-166, 2002.
40. Zhao L, Brown LA, Owji AA, Nunez DJ, Smith DM, Ghatei MA, Bloom SR, and Wilkins MR. Adrenomedullin activity in chronically hypoxic rat lungs. Am J Physiol Heart Circ Physiol 271: H622-H629, 1996.